Solabia is sharpening its strategic focus on cosmetics, nutrition, and life sciences. Backed by private equity firm Astorg, the company aims to become a global leader in natural and biotechnological active ingredients. As part of this strategic repositioning, Solabia plans to divest its microbiological diagnostics division. The group has also announced the appointment of Muriel Koch as President and CEO, effective October 29, 2026.
Strategic repositioning
Muriel Koch succeeds Jean-Baptiste Dellon, who has led Solabia as President and CEO for the past four and a half years. She will oversee the group’s strategic repositioning, including the planned divestment of its microbiological diagnostics division to Oxoid Remel Microbiology, a company acquired by Astorg in August 2026.
Solabia will therefore concentrate its activities on the cosmetics, nutrition, and life sciences markets. Following its acquisition of Mibelle Biochemistry in June 2026, the group has strengthened its position as a leading independent player in the global cosmetic active ingredients market. It now intends to build on its scientific and biotechnological expertise, together with its differentiated portfolio of active ingredients, to drive further international growth.
Muriel Koch brings more than three decades of leadership experience across cosmetics, nutrition and consumer markets, including over twenty years at Nestlé in senior roles across Europe and Asia, and most recently as CEO of Groupe Nuxe, where she has driven its international expansion and modernization. She will work closely with Solabia’s Executive Committee and Astorg to deliver on the company’s growth ambitions.
Acquisition of Ethical Naturals Inc.
As part of this strategic transformation, Solabia has acquired a majority stake in California-based Ethical Naturals Inc. (ENI), a company specializing in the development and marketing of nutraceutical ingredients. Its portfolio includes AlphaWave L-Theanine, GreenGrown Glucosamine, PureLeaf Ginkgo, and Cranberex Cranberry Extract.
Founded in 2006 ENI combines long-standing sourcing expertise with strong scientific, quality assurance and analytical capabilities, serving leading dietary supplement and beverage brands across the U.S. and internationally.
The partnership with ENI will further strengthen Solabia’s nutraceutical ingredients platform while significantly expanding the group’s footprint in the US market. In turn, ENI will benefit from Solabia’s scientific expertise and established European presence to accelerate its growth across the continent.
“The partnership with Ethical Naturals is a perfect illustration of Solabia’s strategic direction as we sharpen our focus on high-value, science-backed ingredients. ENI has built an impressive portfolio of differentiated nutraceutical ingredients, together with a unique focus on quality testing. By combining these strengths with Solabia’s broader portfolio, international reach and innovation capabilities, we see significant opportunities to accelerate growth, particularly in the U.S., and bring even more value to our customers,” said Muriel Koch, President and Chief Executive Officer of Solabia.
ENI’s founders, Cal Bewicke and Leo Liu, will remain shareholders in the company and will continue to manage its development alongside Solabia.
This latest acquisition follows a series of transactions that have marked 2026 for Solabia, beginning with the acquisition of Mibelle Biochemistry, a Swiss specialist in high-performance cosmetic active ingredients, followed by those of Xebios Diagnostics Group and Seqens’ botanical active ingredients and in vitro diagnostics businesses.




























